Odylia announces new partnership with the SATB2 Gene Foundation
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
24 February, 2021
Tiansen Li joins Odylia Advisory Board
“We are very excited to have Tainsen join the Odylia Advisory Board,” said Scott Dorfman, Odylia Therapeutics’ CEO....
09 November, 2020
Odylia and Foundation Fighting Blindness will host a 4-part webinar series starting October 8th
Odylia and Foundation Fighting Blindness are hosting a 4-part preclinical and translational research webinar series. The series will focus on genetic technologies and will provide advice and educational materials to researchers in the rare disease space. If you are currently working in or thinking about preclinical...
21 September, 2020
Sharing Insight for Gene Therapy Manufacturing
Converting vertical information approaches into horizontal solutions for all members of the rare disease community....
04 March, 2020
Ashley Winslow joins the Odylia team
Dr. Winslow will oversee scientific operations and strategy development with a focus on expanding partnerships....
05 November, 2019
Greg Robinson joins Odylia Advisory Board
Dr. Robinson brings extensive biotech experience in gene therapy, ophthalmology and more...
01 October, 2019
Emil Kakkis joins Nonprofit Biotech Odylia Therapeutics Board of Directors
Atlanta, GA August 6, 2019 – Emil Kakkis, MD, PhD, joins the Board of Directors for Odylia Therapeutics. Kakkis is the CEO, President and Founder of Ultragenyx Pharmaceutical Inc., which is committed to developing and commercializing treatments for multiple rare and ultra-rare diseases. He brings...
06 August, 2019
PTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement with Odylia Therapeutics
SOUTH PLAINFIELD, N.J., and BOSTON, M.A. - July 1, 2019 – PTC Therapeutics, Inc. (NASDAQ: PTCT) and Odylia Therapeutics today announced a strategic collaboration to develop novel gene therapies in rare inherited retinal diseases (IRDs) utilizing the Anc80 vector system developed by researchers at Massachusetts...
01 July, 2019
Odylia Therapeutics CEO Featured on Partners4Access Podcast
Scott Dorfman, Odylia Therapeutics CEO, was recently a featured guest on Partners4Access Weekly Podcast. A recording of the podcast entitled “Rare Disease, Cell and Gene Therapy Weekly Roundup” can be found here. Produced by Partners4Access, global experts in access for orphan drug, cell and gene...
13 June, 2019
What is holding back gene therapy for rare diseases?
Odylia CSO Harrison Brown, PhD spoke at the 2019 meeting of the American Society of Gene and Cell Therapy on the issues restricting the development and clinical application of gene therapies for rare genetic diseases. He discussed the specific challenges facing ultra-rare indications, especially those...
02 May, 2019